Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, September 2001, p. 913-921, Vol. 8, No. 5
Division of Viral and Rickettsial
Diseases1 and Division of AIDS, STD, and
TB Laboratory Research,2 National Center for
Infectious Diseases, Centers for Disease Control and Prevention,
Atlanta, Georgia 30333
Received 9 February 2001/Returned for modification 11 April
2001/Accepted 9 May 2001
Improvement of serologic assays for detection of antibodies
against human herpesvirus 8 (HHV-8) is critical to better understand its epidemiology and biology. We produced the HHV-8 latent (ORF73) and
lytic (ORF65, K8.1, and glycoprotein B) antigens in the Semliki Forest
virus system and evaluated their performance in immunofluorescence assays (IFAs) and enzyme-linked immunosorbent assays (ELISAs). These
assays were compared with other latent antigen-based assays, including an IFA based on primary effusion lymphoma (PEL) cells and an ELISA based on bacterially expressed ORF73 antigen, as well as
with other lytic antigen-based assays, including an IFA based
on induced PEL cells, a commercial ELISA based on purified virions, and
ELISAs based on K8.1- and ORF65-derived oligopeptides. We used a panel
of 180 serum specimens obtained from three groups expected to have
high, intermediate, and low HHV-8 prevalences. Using three
different evaluation methods, we found that (i) the performances of the lytic antigen-based ELISAs were almost equivalent, (ii) the lytic antigen-based assays were more sensitive than the latent
antigen-based assays, and (iii) in general, IFAs were more sensitive
than ELISAs based on the same open reading frame. We also found that
serum specimens from healthy individuals contained antibodies
cross-reactive with HHV-8 glycoprotein B that can potentially cause
false-positive reactions in lytic PEL-based IFAs. Although this is not
a substantial problem in most epidemiologic studies, it may confound
the interpretation of data in studies that require high assay
specificity. Because the K8.1-based IFA provides sensitivity similar to
that of lytic PEL-based IFAs and improved specificity, it can be a
useful alternative to the PEL-based IFAs.
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.5.913-921.2001
Comparison of Serologic Assays for Detection of
Antibodies against Human Herpesvirus 8

*
Corresponding author. Mailing address: Centers for
Disease Control and Prevention, MS-G18, 1600 Clifton Rd., Atlanta, GA
30333. Phone: (404) 639-4219. Fax: (404) 639-0049. E-mail:
nai0{at}cdc.gov.
Present address: Biokit S.A., Barcelona, Spain.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»